It recorded a net loss of $3.0 million. Diluted earnings per share were -$0.68.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jul 31, 2026
|
Q1 FY2027
Jul 31, 2026
|
Q4 FY2026
Apr 30, 2026
|
Q3 FY2026
Jan 31, 2026
|
Q2 FY2026
Oct 31, 2025
|
Q1 FY2026
Jul 31, 2025
|
Q3 FY2024
Jan 31, 2025
|
Q2 FY2024
Oct 31, 2024
|
Q1 FY2024
Jul 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Research and development |
3
|
1
-37.6%
|
0
|
1
|
0
|
2
|
0
-84.5%
|
0
|
0
|
| Selling, general and administrative |
6
|
2
+102.2%
|
2
|
1
|
1
|
1
|
1
-76.7%
|
1
|
1
|
| Operating income |
-9
|
-3
-12.0%
|
-3
|
-2
|
-1
|
-3
|
-1
+80.9%
|
-1
|
-1
|
| Net income |
-9
|
-3
-12.0%
|
-3
|
-2
|
-1
|
-3
|
-1
+80.8%
|
-1
|
-1
|
| Net income to common |
—
|
3
|
-3
|
-2
|
-1
|
—
|
—
|
-1
|
—
|
| Basic EPS |
-2.31
|
-0.68
+46.9%
|
-0.72
|
-0.58
|
-0.30
|
-1.28
|
-1.75
-110.8%
|
-3.61
|
-11.42
|
| Diluted EPS |
-2.31
|
-0.68
+46.9%
|
-0.72
|
-0.58
|
-0.30
|
-1.28
|
-1.75
-111.4%
|
-3.61
|
-11.42
|
| Weighted average shares, basic |
4
|
4
+112.7%
|
4
|
4
|
3
|
2
|
1
|
0
|
0
|
| Weighted average shares, diluted |
4
|
4
+112.7%
|
4
|
4
|
3
|
2
|
1
-90.7%
|
0
|
0
|
| Other measures | |||||||||
| Depreciation and amortization |
0
|
0
+0.0%
|
0
|
0
|
0
|
0
|
0
-28.5%
|
0
|
0
|
| EBITDA |
-9
|
-3
-12.2%
|
-3
|
-2
|
-1
|
-3
|
-1
+81.0%
|
-1
|
-1
|
| Interest coverage |
-1,480.55x
|
-1,508.93x
|
-19,139.18x
|
-1,643.72x
|
-376.79x
|
-1,087.48x
|
-513.83x
|
-388.57x
|
-80.16x
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALZN (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- DE
- Headquarters
- Atlanta, GA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1677077
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.